Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202714 | 0.91 | PDE5A (1.00) | PDE5A | |
| SCHEMBL3576801 | 0.88 | PDE5A (0.89) | PDE5A | |
| SCHEMBL6446212 | 0.88 | PDE5A (0.86) | PDE5A | |
| SCHEMBL3576614 | 0.87 | PDE5A (0.86) | PDE5A | |
| SCHEMBL3575752 | 0.87 | PDE5A (0.84) | PDE5A | |
| SCHEMBL3581447 | 0.86 | PDE5A (0.88) | PDE5A | |
| SCHEMBL3576462 | 0.86 | PDE5A (0.82) | PDE5A | |
| SCHEMBL13500483 | 0.85 | PDE5A (0.77) | PDE5A | |
| SCHEMBL3587809 | 0.85 | PDE5A (0.82) | PDE5A | |
| SCHEMBL3583798 | 0.85 | PDE5A (1.00) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180036314-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LP (US) | 2018-02-08 | — | — | US | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20150031704-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LIMITED PARTNERSHIP | 2015-01-29 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20130053393-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LIMITED PARTNERSHIP (US) | 2013-02-28 | — | — | US | claimed |
| EP-2512479-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | Exodos Life Sciences Limited Partnership (US) | 2012-10-24 | — | — | EP | claimed |
| WO-2011075655-A1 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | EXODOS LIFE SCIENCES LIMITED PARTNERSHIP (US) | 2011-06-23 | — | — | WO | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | SPROUT PHARMACEUTICALS, INC. | 2008-05-01 | — | — | US | claimed |
| US-20080051408-A1 | Use of a Pde 5 Inhibitor for Treating and Preventing Hypopigmentary Disorders | SWITCH BIOTECH, LLC | 2008-02-28 | — | — | US | claimed |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | claimed |
| US-20040259792-A1 | Inhibitors of phosphodiesterases in infertility | LABORATOIRES SERONO SA (CH) | 2004-12-23 | — | — | US | claimed |
| WO-2004087211-A2 | INHIBITORS OF PHOSPHODIESTERASES IN INFERTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-10-14 | — | — | WO | claimed |
| US-20040167095-A1 | Use of PDE V inhibitors for improved fecundity in mammals | WESTBROOK SIMON LEMPRIERE (GB) | 2004-08-26 | — | — | US | claimed |
| US-6548508-B2 | Animal growth regulator | PFIZER, INC. | 2003-04-15 | — | — | US | claimed |
| US-20030018037-A1 | Use of PDE V inhibitors for improved fecundity in mammals | SIMON LEMPRIERE WESTBROOK (GB) | 2003-01-23 | — | — | US | claimed |
| US-20030018036-A1 | Use of PDE V inhibitors for improved fecundity in mammals | PFIZER INC. | 2003-01-23 | — | — | US | claimed |
| EP-1199070-A2 | Use of PDE V inhibitors for improved fecundity in mammals | Pfizer Limited (GB) | 2002-04-24 | — | — | EP | claimed |
| US-20020028799-A1 | Treatment of male sexual dysfunction | PFIZER INC. | 2002-03-07 | — | — | US | claimed |
| EP-1157705-A2 | Use of a phosphodiesterase inhibitor in the manufacture of a medicament for blood pressure stabilization during hemodialysis | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167095-A1 | Use of PDE V inhibitors for improved fecundity in mammals | PDE5A, PDE2A, PDE3A | PDE5A 1/4885 |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | PDE5A 27/4885 |
| US-20020028799-A1 | Treatment of male sexual dysfunction | MME, PDE5A, PREP | PDE5A 2/4885 |
| US-20030018036-A1 | Use of PDE V inhibitors for improved fecundity in mammals | PDE5A, PDE2A, PDE3A | PDE5A 1/4885 |
| US-20040259792-A1 | Inhibitors of phosphodiesterases in infertility | PDE5A, PDE2A, PDE3A | PDE5A 1/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE5A 27/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE5A 27/4885 |
| US-20080051408-A1 | Use of a Pde 5 Inhibitor for Treating and Preventing Hypopigmentary Disorders | PDE5A, PDE2A, PDE3A | PDE5A 1/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | PDE5A 27/4885 |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | PDE5A 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.